HCV Treatment
Coverage of the 2015 International AIDS Society Conference
- Details
- Category: HIV Treatment
- Published on Monday, 06 July 2015 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), July 19-22, in Vancouver, Canada.
Conference highlights include HIV treatment as prevention, pre-exposure prophylaxis (PrEP), new antiretroviral therapies, HIV cure research, hepatitis C and HIV/HCV coinfection, and global scale-up of prevention and treatment.
7/22/15
Updated Hepatitis C Care and Treatment Guidelines Published in Hepatology
- Details
- Category: HCV Treatment Guidelines
- Published on Friday, 03 July 2015 00:00
- Written by Wiley
The latest updated U.S. recommendations for hepatitis C testing, management, and treatment, compiled by an expert panel of members of the American Association for the Study of Liver Diseases (AASLD) and partner organizations, have been published in the June 25 advance online edition of Hepatology, the AASLD's professional journal.
Viekira Pak Regimen Cures 100% of Genotype 1b Hepatitis C Patients with Cirrhosis
- Details
- Category: Approved HCV Drugs
- Published on Friday, 26 June 2015 00:00
- Written by AbbVie
All participants in the TURQUOISE-III trial, which enrolled HCV genotype 1b patients with compensated liver cirrhosis, achieved sustained virological response using AbbVie's Viekira Pak or "3D" regimen without ribavirin, according to a company announcement this week.
Adding Ribavirin to Harvoni for Hepatitis C Increases Side Effects But Not Efficacy
- Details
- Category: Approved HCV Drugs
- Published on Friday, 26 June 2015 00:00
- Written by Liz Highleyman
Combining sofosbuvir/ledipasvir (Harvoni) with ribavirin was associated with a greater likelihood of adverse events and laboratory abnormalities, but did not significantly increase the chances of sustained response for genotype 1 chronic hepatitis patients compared to sofosbuvir/ledipasvir alone, according to an analysis of the Phase 3 ION trials described in the July edition of Hepatology.
Merck Submits Grazoprevir/ Elbasvir for FDA Approval, BMS Gets Breakthrough Status for Daclatasvir
- Details
- Category: HCV Treatment
- Published on Wednesday, 10 June 2015 00:00
- Written by Merck, BMS
Merck has requested U.S. Food and Drug Administration (FDA) approval for its promising grazoprevir/elbasvir coformulation for people with hepatitis C virus genotypes 1, 4, or 6, the company recently announced. In related news, Bristol-Myers Squibb said that the FDA has granted Breakthrough Therapy status for daclatasvir plus sofosbuvir for people with advanced cirrhosis and liver transplant recipients.
More Articles...
- DDW 2015: Sofosbuvir/ Ledipasvir Cures Most Hepatitis C Patients with Cirrhosis
- DDW 2015: Sofosbuvir + Daclatasvir for 12 Weeks Cures Most HIV/HCV Coinfected Patients
- EASL 2015: Liver Function and Survival Improve after Hepatitis C Treatment with Viekira Pak
- EASL 2015: Hepatitis C Treatment May Be Highly Cost-effective for Prisoners in England
Web Design and Development by